Further studies are needed to explore whether this effect is EMPA specific or common to SGLT2 inhibitors in general, and whether EMPA administration can diminish arrhythmia vulnerability in patients with DMD. The gene discussed is SLC5A2; the disease is cardiac arrhythmia.